Search results for "TC"

showing 10 items of 9993 documents

Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe

2001

The aim of this study was to evaluate the distribution and clinical significance of hepatitis C virus (HCV) genotypes in European patients with compensated cirrhosis due to hepatitis C (Child class A) seen at tertiary referral centres. HCV genotypes were determined by genotype-specific primer PCR in 255 stored serum samples obtained from cirrhotics followed for a median period of 7 years. Inclusion criteria were biopsy-proven cirrhosis, absence of complications of cirrhosis and exclusion of all other potential causes of chronic liver disease. The proportion of patients with types 1b, 2, 3a, 1a, 4 and 5 were 69%, 19%, 6%, 5%, 0.5% and 0.5%, respectively. Kaplan-Meier 5-year risk of hepatocel…

AdultLiver CirrhosisMalemedicine.medical_specialtyPathologyCirrhosisHepacivirusHepatitis C virusHepacivirusAntibodies ViralChronic liver diseasemedicine.disease_causeAntiviral AgentsGastroenterologyDisease-Free SurvivalStatistics NonparametricSex FactorsSDG 3 - Good Health and Well-beingVirologyInternal medicineHumansMedicineDecompensationLongitudinal StudiesAgedProportional Hazards ModelsHepatologybiologybusiness.industryAge FactorsInterferon-alphaTransfusion ReactionHepatitis CMiddle Agedmedicine.diseasebiology.organism_classificationHepatitis CEuropeTreatment OutcomeInfectious DiseasesRelative riskHepatocellular carcinomaRNA ViralFemalebusiness
researchProduct

Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group

2020

Background: Worldwide multiple sclerosis (MS) centers have coordinated their efforts to use data acquired in clinical practice for real-world observational studies. In this retrospective study, we aim to harmonize outcome measures, and to evaluate their heterogeneity within the Rising Italian Researchers in MS (RIReMS) study group. Methods: RIReMS members filled in a structured questionnaire evaluating the use of different outcome measures in clinical practice. Thereafter, thirty-four already-published papers from RIReMS centers were used for heterogeneity analyses, using the DerSimonian and Laird random-effects method to compute the between-study variance (τ2). Results: Based on questionna…

AdultLongitudinal studymedicine.medical_specialtyHarmonizationOutcome measuresMultiple sclerosisOutcome measure03 medical and health sciences0302 clinical medicineHarmonization; Multiple sclerosis; Outcome measures; Real worldmedicineHumansMultiple sclerosi030212 general & internal medicineAge of OnsetAgedRetrospective StudiesExpanded Disability Status Scalebusiness.industryMultiple sclerosisOutcome measuresRetrospective cohort studyReal worldGeneral MedicineVariance (accounting)medicine.diseaseNeurologyItalyHarmonizationFamily medicineObservational studyFemaleNeurology (clinical)business030217 neurology & neurosurgeryHarmonization; Multiple sclerosis; Outcome measures; Real world; Adult; Age of Onset; Aged; Female; Humans; Italy; Retrospective Studies; Multiple Sclerosis
researchProduct

Vitamin D as an effective treatment in human uterine leiomyomas independent of mediator complex subunit 12 mutation.

2021

Objective To study whether vitamin D (VitD) inhibits cell proliferation and Wnt/β-catenin and transforming growth factor−β (TGFβ) signaling pathways in uterine leiomyomas independent of mediator complex subunit 12 (MED12) mutation status. Design Prospective study comparing leiomyoma vs. myometrial tissues and human uterine leiomyoma primary (HULP) cells treated with or without VitD and analyzed by MED12 mutation status. Setting Hospital and university laboratories. Patient(s) Women with uterine leiomyoma without any treatment (n = 37). Intervention(s) Uterine leiomyoma and myometrium samples were collected from women undergoing surgery because of symptomatic leiomyoma pathology. Main Outcom…

AdultMMP9MED12AndrologyWNT4medicineVitamin D and neurologyHumansProspective StudiesVitamin DneoplasmsCells CulturedCell ProliferationUterine leiomyomaMediator ComplexLeiomyomabusiness.industryWnt signaling pathwayMyometriumObstetrics and GynecologyMiddle Agedmusculoskeletal systemmedicine.diseasefemale genital diseases and pregnancy complicationsLeiomyomaTreatment OutcomeReproductive MedicineMutationUterine NeoplasmsFemalebusinessFertility and sterility
researchProduct

Human voice pitch measures are robust across a variety of speech recordings: methodological and theoretical implications

2021

Fundamental frequency ( f o ), perceived as voice pitch, is the most sexually dimorphic, perceptually salient and intensively studied voice parameter in human nonverbal communication. Thousands of studies have linked human f o to biological and social speaker traits and life outcomes, from reproductive to economic. Critically, researchers have used myriad speech stimuli to measure f o and infer its functional relevance, from individual vowels to longer bouts of spontaneous speech. Here, we acoustically analysed f o in nearly 1000 affectively neutral speech utterances (vowels, words, counting, greetings, read paragraphs and free spontaneous speech) produced by the same 154 men and women, ag…

AdultMale0106 biological sciencesVoice pitchspeech[SHS.ANTHRO-BIO]Humanities and Social Sciences/Biological anthropologyBiology010603 evolutionary biology01 natural sciencesSpeech Acousticsbiomechanics03 medical and health sciencesNonverbal communicationsource-filter theoryHumanssexual selectionHuman voice030304 developmental biology0303 health sciencesCommunication[SHS.STAT]Humanities and Social Sciences/Methods and statisticsbusiness.industryevolution fundamental frequencyFundamental frequencyVariety (linguistics)Agricultural and Biological Sciences (miscellaneous)behaviourSalientSexual selection[SCCO.PSYC]Cognitive science/PsychologyVoicenonverbal communicationFemaleAnimal BehaviourGeneral Agricultural and Biological SciencesbusinessBiology Letters
researchProduct

Working Alliance Inventory for Online Interventions-Short Form (WAI-TECH-SF): The Role of the Therapeutic Alliance between Patient and Online Program…

2020

Background: Therapeutic alliance (TA) between the patient and therapist has been related to positive therapeutic outcomes. Because Internet-based interventions are increasingly being implemented, a tool is needed to measure the TA with Internet-based self-guided programs. The Working Alliance Inventory for online interventions (WAI-TECH-SF) was adapted based on the WAI Short Form (Hatcher &amp

AdultMale020205 medical informaticsAdolescentPsychometricsonline interventionsTherapeutic AllianceHealth Toxicology and MutagenesisPsychological interventionlcsh:MedicineTherapeutic alliance02 engineering and technologytherapeutic outcomesArticle03 medical and health sciencesYoung Adult0302 clinical medicineBehavior TherapyInternal consistencySurveys and QuestionnairesCredibility0202 electrical engineering electronic engineering information engineeringHumans030212 general & internal medicineOnline interventionsDepressive symptomsAgedTherapeutic outcomesDepressionlcsh:RPublic Health Environmental and Occupational HealthReproducibility of ResultsProfessional-Patient RelationsMiddle AgedExploratory factor analysis3. Good healthAllianceTreatment OutcomeSatisfaction with the treatmentPatient Satisfactionsatisfaction with the treatmentFemalePsychologyInternet-Based InterventionClinical psychologyInternational journal of environmental research and public health
researchProduct

Effects of photodynamic therapy in periodontal treatment: A randomized, controlled clinical trial

2017

Aim To evaluate the effects of photodynamic therapy (PDT) in the nonsurgical treatment of chronic periodontitis. Materials and methods A randomized, single-blind, controlled, parallel-group clinical trial was performed. Sixty patients were enrolled: 20 healthy controls and 40 patients with periodontitis. The 40 patients were randomized for scaling and root planing (SRP) or SRP+PDT. Periodontal (plaque index, probing depth, clinical recession, clinical attachment level, bleeding on probing, and gingival crevicular fluid volume, corresponding to 381 vs 428 critical sites), microbiological (Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Tannerella forsythia, Treponema dentico…

AdultMale0301 basic medicine030103 biophysicsmedicine.medical_specialtyBleeding on probingDentistryenvironment and public healthGastroenterologyRoot Planing03 medical and health sciences0302 clinical medicineScaling and root planingInternal medicinemedicineHumansTannerella forsythiaSingle-Blind MethodAgedPeriodontitisbiologybusiness.industryPrevotella intermediaAggregatibacter actinomycetemcomitansCampylobacter rectus030206 dentistryMiddle Agedbiology.organism_classificationmedicine.diseaseChronic periodontitisTreatment OutcomePhotochemotherapyChronic PeriodontitisDental ScalingPeriodonticsFemalePeriodontal Indexmedicine.symptombusinessBiomarkersJournal of Clinical Periodontology
researchProduct

All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-0…

2016

The aim of this clinical trial was to evaluate the impact of all-trans retinoic acid (ATRA) in combination with chemotherapy and to assess the NPM1 status as biomarker for ATRA therapy in younger adult patients (18–60 years) with acute myeloid leukemia (AML). Patients were randomized for intensive chemotherapy with or without open-label ATRA (45 mg/m2, days 6–8; 15 mg/m2, days 9–21). Two cycles of induction therapy were followed by risk-adapted consolidation with high-dose cytarabine or allogeneic hematopoietic cell transplantation. Due to the open label character of the study, analysis was performed on an intention-to-treat (ITT) and a per-protocol (PP) basis. One thousand one hundred pati…

AdultMale0301 basic medicineAcute promyelocytic leukemiaOncologymedicine.medical_specialtyNPM1Adolescentmedicine.medical_treatmentTretinoinYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansddc:610ChemotherapyAcute myeloid leukemiaHematologyAll-trans retinoic acidbusiness.industryMyeloid leukemiaInduction ChemotherapyHematologyGeneral MedicineMiddle Agedmedicine.disease3. Good healthSurgerySurvival RateTransplantationClinical trialLeukemia Myeloid AcuteTreatment Outcome030104 developmental biologyNucleophosmin-1Acute myeloid leukemia; All-trans retinoic acid; Nucleophosmin-1030220 oncology & carcinogenesisCytarabineFemaleOriginal ArticlebusinessNucleophosminFollow-Up Studiesmedicine.drug
researchProduct

Induction of antitoxin responses in Clostridium-difficile-infected patients compared to healthy blood donors

2016

According to the literature Clostridium difficile antitoxins are present in up to 66% of humans. In a survey of ∼400 plasma samples from healthy blood donors we found that less than 6% were positive for anti-TcdA or anti-TcdB antitoxins. Using the same standard immunoassay protocol, we looked for IgG and IgA antitoxins in the blood and stool samples from 25 patients with C. difficile infection (CDI). Some patients with CDI had no antitoxin detected at all, while others had high levels of specific IgG- and IgA-antitoxins against both TcdA and TcdB in blood and IgA-anti-TcdA and -anti-TcdB antibodies in stool. Systemic responses to TcdB and mucosal responses to TcdA predominated. Among patien…

AdultMale0301 basic medicineAdolescentBacterial ToxinsClostridium difficile toxin ABlood DonorsBiologyMicrobiologyMicrobiologyYoung Adult03 medical and health sciences0302 clinical medicineImmune systemmedicineHumans030212 general & internal medicineEnterocolitis PseudomembranousAgedAntigens Bacterialmedicine.diagnostic_testClostridioides difficileCase-control studyMiddle AgedClostridium difficileAntibodies BacterialMolecular TypingTreatment Outcome030104 developmental biologyInfectious DiseasesCase-Control StudiesImmunoassayImmunologyHumoral immunitybiology.proteinFemaleAntitoxinAntibodyAnaerobe
researchProduct

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractor…

2018

AbstractPurpose:Here, we report results of the first phase I study of erdafitinib, a potent, oral pan-FGFR inhibitor.Patients and Methods:Patients age ≥18 years with advanced solid tumors for which standard antineoplastic therapy was no longer effective were enrolled (NCT01703481). Parts 2 to 4 employed molecular screening for activating FGFR genomic alterations. In patients with such alterations, two selected doses/schedules identified during part 1 dose-escalation [9 mg once daily and 10 mg intermittently (7 days on/7 days off), as previously published (Tabernero JCO 2015;33:3401-8)] were tested.Results:The study included 187 patients. The most common treatment-related adverse events were…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyAdministration OralAntineoplastic AgentsDrug resistanceGastroenterologyYoung Adult03 medical and health sciencesHyperphosphatemia0302 clinical medicineRefractoryErdafitinibNeoplasmsQuinoxalinesInternal medicinemedicineHumansNeoplasmDosingAdverse effectProtein Kinase InhibitorsAgedNeoplasm StagingAged 80 and overbusiness.industryGenetic VariationMiddle AgedPrognosismedicine.diseaseReceptors Fibroblast Growth FactorTreatment Outcome030104 developmental biologyOncologyTolerabilityDrug Resistance Neoplasm030220 oncology & carcinogenesisRetreatmentPyrazolesFemalebusinessClinical Cancer Research
researchProduct

Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306)

2016

We explored the association of early tumor shrinkage (ETS) and non-ETS with efficacy of first-line and consecutive second-line treatment in patients with KRAS wild-type metastatic colorectal cancer treated in FIRE-3. Assessment of tumor shrinkage was based on the sum of longest diameters of target lesions, evaluated after 6 weeks of treatment. Shrinkage was classified as ETS (shrinkage by ≥ 20%), mETS (shrinkage by 0 to20%), mPD (minor progression0 to20%) and PD (progression ≥20%). Overall survival (OS) was 33.2 (95% CI 28.0-38.4) months in ETS patients, while non-ETS was associated with less favorable outcome (mETS 24.0 (95% CI 21.2-26.9) months, mPD 19.0 (95% CI 13.0-25.0) months, PD 12.8…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancerLeucovorinCetuximabKaplan-Meier Estimatemedicine.disease_causeGastroenterologyDisease-Free SurvivalProto-Oncogene Proteins p21(ras)03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedShrinkageCetuximabbusiness.industryRemission InductionTumor shrinkageMiddle Agedmedicine.diseaseBevacizumabTreatment Outcome030104 developmental biologyOncologyFluorouracil030220 oncology & carcinogenesisFOLFIRICamptothecinFemaleFluorouracilKRASColorectal Neoplasmsbusinessmedicine.drugInternational Journal of Cancer
researchProduct